DELTOS
"DELTOS" is a word mark owned by Romix Biosciences Inc., filed at the USPTO on October 15, 2026. It is under examination and covers classes 42 and 44.
- Status
- Under examination
- Since October 15, 2026
- Filed
- October 15, 2026
- Registered
- Not yet
- Expires
- Not recorded
- Application no.
- 50163302
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 2 classes
Who owns DELTOS
The owner and representative on file with the office.
Owner
Romix Biosciences Inc.
Boston, United States
Representative
Aaron D. Hendelman
Wilson Sonsini Goodrich & Rosati
What the mark covers
The products and services DELTOS is filed for, grouped by Nice class.
Pharmaceutical research and development; Scientific research and development, namely, inputting, collecting, defining, modeling, analyzing, and validating data related to biomarkers for the purposes of drug development and diagnostics; Customizing computer software related to inputting, collecting, defining, modeling, analyzing, and validating data related to biomarkers for the purposes of drug development and diagnostics; Scientific research and development services in the fields of liquid biopsy, cell-free nucleic acids, cell-free RNA, cell-free DNA, proteomics, and transcriptomics; Scientific research services, namely, next-generation sequencing and profiling of cell-free RNA and cell-free DNA from blood and other bodily fluid samples for research purposes; Scientific research services, namely, proteomic profiling and analysis of proteins and peptides in blood and other bodily fluid samples for research purposes; Scientific laboratory services, namely, isolation, preparation, and analysis of nucleic acids and proteins from bodily fluid samples for research purposes; Drug discovery and development services, namely, identification and validation of biomarkers and drug targets through analysis of cell-free nucleic acids and proteins; Providing scientific research and development services to pharmaceutical and biotechnology companies in the fields of disease biology, biomarker discovery, patient stratification, and therapeutic activity assessment; Scientific research services in the field of clinical trial support, namely, biomarker analysis of patient samples for research purposes; Bioinformatics services for scientific research purposes, namely, analysis and interpretation of nucleic acid sequencing data and proteomic data; Software as a service (SaaS) services featuring software for analyzing, modeling, and visualizing cell-free nucleic acid sequencing data, proteomic data, and biomarker data for scientific research purposes; Software as a service (SaaS) services featuring software that uses artificial intelligence and machine learning for identifying disease-associated patterns in nucleic acid sequencing data and proteomic data for scientific research purposes; Providing temporary use of online non-downloadable software for collecting, managing, and analyzing biomarker data for drug development; Platform as a service (PaaS) featuring computer software platforms for biomarker data analysis for scientific research purposes; Computer software design, development, and programming services for others in the field of bioinformatics and biomarker analysis; Technological consulting services in the fields of liquid biopsy, cell-free nucleic acid analysis, proteomics, and biomarker data analysis
Medical testing services for diagnostic or treatment purposes, namely, analysis of cell-free RNA and cell-free DNA from blood and other bodily fluid samples; Medical testing services for diagnostic or treatment purposes, namely, analysis of proteins and peptides in blood and other bodily fluid samples; Medical laboratory services, namely, analysis of blood and other bodily fluid samples to provide information to healthcare professionals; Clinical laboratory testing services, namely, molecular profiling of blood and other bodily fluid samples for diagnostic or treatment purposes; Liquid biopsy testing services for medical diagnostic or treatment purposes; Medical laboratory services in support of clinical trials, namely, analysis of patient blood and other bodily fluid samples for diagnostic or treatment purposes; Medical diagnostic services, namely, detection, diagnosis, and monitoring of disease through molecular profiling of cell-free nucleic acids and proteins; Medical screening services, namely, analysis of blood and other bodily fluid samples to identify disease-associated biomarkers; Providing medical information to healthcare professionals and patients in the form of reports in the field of molecular profiling of cell-free nucleic acids and proteins for the diagnosis, treatment, and monitoring of diseases; Medical consulting services, namely, interpretation of molecular testing and profiling results for healthcare professionals
What has happened so far
Steps recorded by the USPTO, newest first.
- Application filing receipt mailed
- New application entered
About DELTOS
Who owns the trademark "DELTOS"?
The USPTO trademark "DELTOS" (application 50163302) is owned by Romix Biosciences Inc.
What is the status of "DELTOS"?
Its status at the USPTO is: under examination.
Get this data via the API
Everything on this page comes from the Signa API. Pull DELTOS and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_01a144d0-94f0-729e-957f-9a080f01bc94
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_01a144d0-94f0-729e-957f-9a080f01bc94",
"object": "trademark",
"mark_text": "DELTOS",
"status": {
"primary": "pending",
"stage": "examining"
},
"office_code": "US",
"application_number": "50163302",
"filing_date": "2026-10-15",
"nice_classes": [
42,
44
],
"owners": [
{
"name": "Romix Biosciences Inc.",
"entity_id": null
}
]
}